Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK)
HKD 0.67
(0.0%)
HKD 0.67
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.25 Billion CNY | 5.2% |
| 2022 | 1.19 Billion CNY | 10.46% |
| 2021 | 1.08 Billion CNY | 43.22% |
| 2020 | 755.05 Million CNY | 3884.45% |
| 2019 | 18.95 Million CNY | -80.05% |
| 2018 | 95 Million CNY | 0.0% |
| 2017 | - CNY | -100.0% |
| 2016 | 8.28 Million CNY | 0.0% |
| 2015 | 8.28 Million CNY | 136.57% |
| 2014 | 3.5 Million CNY | -98.13% |
| 2013 | 186.68 Million CNY | -75.85% |
| 2012 | 773.11 Million CNY | 13048.2% |
| 2011 | 5.88 Million CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| 2008 | - CNY | -100.0% |
| 2007 | 12 Million CNY | -25.0% |
| 2006 | 16 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.08 Billion CNY | 0.0% |
| 2023 FY | 1.25 Billion CNY | 5.2% |
| 2023 Q4 | 1.25 Billion CNY | 0.0% |
| 2023 Q2 | 1.33 Billion CNY | 0.0% |
| 2022 FY | 1.19 Billion CNY | 10.46% |
| 2022 Q2 | 1.17 Billion CNY | 0.0% |
| 2022 Q4 | 1.19 Billion CNY | 0.0% |
| 2021 FY | 1.08 Billion CNY | 43.22% |
| 2021 Q2 | 815.33 Million CNY | 0.0% |
| 2021 Q4 | 1.08 Billion CNY | 0.0% |
| 2020 Q4 | 755.05 Million CNY | 0.0% |
| 2020 Q2 | 590.97 Million CNY | 0.0% |
| 2020 FY | 755.05 Million CNY | 3884.45% |
| 2019 FY | 18.95 Million CNY | -80.05% |
| 2019 Q2 | 10.9 Million CNY | 0.0% |
| 2019 Q4 | 18.95 Million CNY | 0.0% |
| 2018 Q4 | 95 Million CNY | 0.0% |
| 2018 Q2 | 210.9 Million CNY | 0.0% |
| 2018 FY | 95 Million CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 FY | - CNY | -100.0% |
| 2017 Q2 | 3.5 Million CNY | 0.0% |
| 2016 Q2 | 8.28 Million CNY | 0.0% |
| 2016 Q4 | 8.28 Million CNY | 0.0% |
| 2016 FY | 8.28 Million CNY | 0.0% |
| 2015 Q4 | 8.28 Million CNY | 0.0% |
| 2015 Q2 | 3.5 Million CNY | 0.0% |
| 2015 FY | 8.28 Million CNY | 136.57% |
| 2014 Q2 | - CNY | 0.0% |
| 2014 Q4 | 3.5 Million CNY | 0.0% |
| 2014 FY | 3.5 Million CNY | -98.13% |
| 2013 Q2 | 531 Million CNY | 0.0% |
| 2013 Q4 | 186.68 Million CNY | 0.0% |
| 2013 FY | 186.68 Million CNY | -75.85% |
| 2012 FY | 773.11 Million CNY | 13048.2% |
| 2012 Q4 | 773.11 Million CNY | 0.0% |
| 2012 Q2 | 503.41 Million CNY | 0.0% |
| 2011 Q4 | 5.88 Million CNY | 0.0% |
| 2011 FY | 5.88 Million CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| 2008 FY | - CNY | -100.0% |
| 2007 FY | 12 Million CNY | -25.0% |
| 2006 FY | 16 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -18353.116% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 63.086% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -943.648% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | -172.624% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -257940.452% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -515.586% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -327.402% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | -276.444% |
| PuraPharm Corporation Limited | 424.77 Million HKD | -195.844% |
| SSY Group Limited | 3.37 Billion HKD | 62.756% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -841.972% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | -67.693% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 98.536% |